Cargando…
LMO3 reprograms visceral adipocyte metabolism during obesity
ABSTRACT: Obesity and body fat distribution are important risk factors for the development of type 2 diabetes and metabolic syndrome. Evidence has accumulated that this risk is related to intrinsic differences in behavior of adipocytes in different fat depots. We recently identified LIM domain only...
Autores principales: | , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8313462/ https://www.ncbi.nlm.nih.gov/pubmed/34018016 http://dx.doi.org/10.1007/s00109-021-02089-9 |
_version_ | 1783729353919561728 |
---|---|
author | Wagner, Gabriel Fenzl, Anna Lindroos-Christensen, Josefine Einwallner, Elisa Husa, Julia Witzeneder, Nadine Rauscher, Sabine Gröger, Marion Derdak, Sophia Mohr, Thomas Sutterlüty, Hedwig Klinglmüller, Florian Wolkerstorfer, Silviya Fondi, Martina Hoermann, Gregor Cao, Lei Wagner, Oswald Kiefer, Florian W. Esterbauer, Harald Bilban, Martin |
author_facet | Wagner, Gabriel Fenzl, Anna Lindroos-Christensen, Josefine Einwallner, Elisa Husa, Julia Witzeneder, Nadine Rauscher, Sabine Gröger, Marion Derdak, Sophia Mohr, Thomas Sutterlüty, Hedwig Klinglmüller, Florian Wolkerstorfer, Silviya Fondi, Martina Hoermann, Gregor Cao, Lei Wagner, Oswald Kiefer, Florian W. Esterbauer, Harald Bilban, Martin |
author_sort | Wagner, Gabriel |
collection | PubMed |
description | ABSTRACT: Obesity and body fat distribution are important risk factors for the development of type 2 diabetes and metabolic syndrome. Evidence has accumulated that this risk is related to intrinsic differences in behavior of adipocytes in different fat depots. We recently identified LIM domain only 3 (LMO3) in human mature visceral adipocytes; however, its function in these cells is currently unknown. The aim of this study was to determine the potential involvement of LMO3-dependent pathways in the modulation of key functions of mature adipocytes during obesity. Based on a recently engineered hybrid rAAV serotype Rec2 shown to efficiently transduce both brown adipose tissue (BAT) and white adipose tissue (WAT), we delivered YFP or Lmo3 to epididymal WAT (eWAT) of C57Bl6/J mice on a high-fat diet (HFD). The effects of eWAT transduction on metabolic parameters were evaluated 10 weeks later. To further define the role of LMO3 in insulin-stimulated glucose uptake, insulin signaling, adipocyte bioenergetics, as well as endocrine function, experiments were conducted in 3T3-L1 adipocytes and newly differentiated human primary mature adipocytes, engineered for transient gain or loss of LMO3 expression, respectively. AAV transduction of eWAT results in strong and stable Lmo3 expression specifically in the adipocyte fraction over a course of 10 weeks with HFD feeding. LMO3 expression in eWAT significantly improved insulin sensitivity and healthy visceral adipose tissue expansion in diet-induced obesity, paralleled by increased serum adiponectin. In vitro, LMO3 expression in 3T3-L1 adipocytes increased PPARγ transcriptional activity, insulin-stimulated GLUT4 translocation and glucose uptake, as well as mitochondrial oxidative capacity in addition to fatty acid oxidation. Mechanistically, LMO3 induced the PPARγ coregulator Ncoa1, which was required for LMO3 to enhance glucose uptake and mitochondrial oxidative gene expression. In human mature adipocytes, LMO3 overexpression promoted, while silencing of LMO3 suppressed mitochondrial oxidative capacity. LMO3 expression in visceral adipose tissue regulates multiple genes that preserve adipose tissue functionality during obesity, such as glucose metabolism, insulin sensitivity, mitochondrial function, and adiponectin secretion. Together with increased PPARγ activity and Ncoa1 expression, these gene expression changes promote insulin-induced GLUT4 translocation, glucose uptake in addition to increased mitochondrial oxidative capacity, limiting HFD-induced adipose dysfunction. These data add LMO3 as a novel regulator improving visceral adipose tissue function during obesity. KEY MESSAGES: LMO3 increases beneficial visceral adipose tissue expansion and insulin sensitivity in vivo. LMO3 increases glucose uptake and oxidative mitochondrial activity in adipocytes. LMO3 increases nuclear coactivator 1 (Ncoa1). LMO3-enhanced glucose uptake and mitochondrial gene expression requires Ncoa1. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00109-021-02089-9. |
format | Online Article Text |
id | pubmed-8313462 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Springer Berlin Heidelberg |
record_format | MEDLINE/PubMed |
spelling | pubmed-83134622021-08-16 LMO3 reprograms visceral adipocyte metabolism during obesity Wagner, Gabriel Fenzl, Anna Lindroos-Christensen, Josefine Einwallner, Elisa Husa, Julia Witzeneder, Nadine Rauscher, Sabine Gröger, Marion Derdak, Sophia Mohr, Thomas Sutterlüty, Hedwig Klinglmüller, Florian Wolkerstorfer, Silviya Fondi, Martina Hoermann, Gregor Cao, Lei Wagner, Oswald Kiefer, Florian W. Esterbauer, Harald Bilban, Martin J Mol Med (Berl) Original Article ABSTRACT: Obesity and body fat distribution are important risk factors for the development of type 2 diabetes and metabolic syndrome. Evidence has accumulated that this risk is related to intrinsic differences in behavior of adipocytes in different fat depots. We recently identified LIM domain only 3 (LMO3) in human mature visceral adipocytes; however, its function in these cells is currently unknown. The aim of this study was to determine the potential involvement of LMO3-dependent pathways in the modulation of key functions of mature adipocytes during obesity. Based on a recently engineered hybrid rAAV serotype Rec2 shown to efficiently transduce both brown adipose tissue (BAT) and white adipose tissue (WAT), we delivered YFP or Lmo3 to epididymal WAT (eWAT) of C57Bl6/J mice on a high-fat diet (HFD). The effects of eWAT transduction on metabolic parameters were evaluated 10 weeks later. To further define the role of LMO3 in insulin-stimulated glucose uptake, insulin signaling, adipocyte bioenergetics, as well as endocrine function, experiments were conducted in 3T3-L1 adipocytes and newly differentiated human primary mature adipocytes, engineered for transient gain or loss of LMO3 expression, respectively. AAV transduction of eWAT results in strong and stable Lmo3 expression specifically in the adipocyte fraction over a course of 10 weeks with HFD feeding. LMO3 expression in eWAT significantly improved insulin sensitivity and healthy visceral adipose tissue expansion in diet-induced obesity, paralleled by increased serum adiponectin. In vitro, LMO3 expression in 3T3-L1 adipocytes increased PPARγ transcriptional activity, insulin-stimulated GLUT4 translocation and glucose uptake, as well as mitochondrial oxidative capacity in addition to fatty acid oxidation. Mechanistically, LMO3 induced the PPARγ coregulator Ncoa1, which was required for LMO3 to enhance glucose uptake and mitochondrial oxidative gene expression. In human mature adipocytes, LMO3 overexpression promoted, while silencing of LMO3 suppressed mitochondrial oxidative capacity. LMO3 expression in visceral adipose tissue regulates multiple genes that preserve adipose tissue functionality during obesity, such as glucose metabolism, insulin sensitivity, mitochondrial function, and adiponectin secretion. Together with increased PPARγ activity and Ncoa1 expression, these gene expression changes promote insulin-induced GLUT4 translocation, glucose uptake in addition to increased mitochondrial oxidative capacity, limiting HFD-induced adipose dysfunction. These data add LMO3 as a novel regulator improving visceral adipose tissue function during obesity. KEY MESSAGES: LMO3 increases beneficial visceral adipose tissue expansion and insulin sensitivity in vivo. LMO3 increases glucose uptake and oxidative mitochondrial activity in adipocytes. LMO3 increases nuclear coactivator 1 (Ncoa1). LMO3-enhanced glucose uptake and mitochondrial gene expression requires Ncoa1. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00109-021-02089-9. Springer Berlin Heidelberg 2021-05-20 2021 /pmc/articles/PMC8313462/ /pubmed/34018016 http://dx.doi.org/10.1007/s00109-021-02089-9 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Original Article Wagner, Gabriel Fenzl, Anna Lindroos-Christensen, Josefine Einwallner, Elisa Husa, Julia Witzeneder, Nadine Rauscher, Sabine Gröger, Marion Derdak, Sophia Mohr, Thomas Sutterlüty, Hedwig Klinglmüller, Florian Wolkerstorfer, Silviya Fondi, Martina Hoermann, Gregor Cao, Lei Wagner, Oswald Kiefer, Florian W. Esterbauer, Harald Bilban, Martin LMO3 reprograms visceral adipocyte metabolism during obesity |
title | LMO3 reprograms visceral adipocyte metabolism during obesity |
title_full | LMO3 reprograms visceral adipocyte metabolism during obesity |
title_fullStr | LMO3 reprograms visceral adipocyte metabolism during obesity |
title_full_unstemmed | LMO3 reprograms visceral adipocyte metabolism during obesity |
title_short | LMO3 reprograms visceral adipocyte metabolism during obesity |
title_sort | lmo3 reprograms visceral adipocyte metabolism during obesity |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8313462/ https://www.ncbi.nlm.nih.gov/pubmed/34018016 http://dx.doi.org/10.1007/s00109-021-02089-9 |
work_keys_str_mv | AT wagnergabriel lmo3reprogramsvisceraladipocytemetabolismduringobesity AT fenzlanna lmo3reprogramsvisceraladipocytemetabolismduringobesity AT lindrooschristensenjosefine lmo3reprogramsvisceraladipocytemetabolismduringobesity AT einwallnerelisa lmo3reprogramsvisceraladipocytemetabolismduringobesity AT husajulia lmo3reprogramsvisceraladipocytemetabolismduringobesity AT witzenedernadine lmo3reprogramsvisceraladipocytemetabolismduringobesity AT rauschersabine lmo3reprogramsvisceraladipocytemetabolismduringobesity AT grogermarion lmo3reprogramsvisceraladipocytemetabolismduringobesity AT derdaksophia lmo3reprogramsvisceraladipocytemetabolismduringobesity AT mohrthomas lmo3reprogramsvisceraladipocytemetabolismduringobesity AT sutterlutyhedwig lmo3reprogramsvisceraladipocytemetabolismduringobesity AT klinglmullerflorian lmo3reprogramsvisceraladipocytemetabolismduringobesity AT wolkerstorfersilviya lmo3reprogramsvisceraladipocytemetabolismduringobesity AT fondimartina lmo3reprogramsvisceraladipocytemetabolismduringobesity AT hoermanngregor lmo3reprogramsvisceraladipocytemetabolismduringobesity AT caolei lmo3reprogramsvisceraladipocytemetabolismduringobesity AT wagneroswald lmo3reprogramsvisceraladipocytemetabolismduringobesity AT kieferflorianw lmo3reprogramsvisceraladipocytemetabolismduringobesity AT esterbauerharald lmo3reprogramsvisceraladipocytemetabolismduringobesity AT bilbanmartin lmo3reprogramsvisceraladipocytemetabolismduringobesity |